About Oraloncolytics
Oraloncolytics is a company based in United States founded in 2018 by Shanthu Kere. It operates as a B2B. Oraloncolytics operates in a competitive market with competitors including Flatiron Health, Charm Health, Electronic Registry Systems, Jana Analysis and Asthenis, among others.
- Headquarter United States
- Founders Shanthu Kere
- SectorsHealthcare
- Website oraloncolytics.com
People of Oraloncolytics
1 people are tracked at Oraloncolytics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Shanthu Kere | Founder, CEO | Leadership |
Complete people profiles for Oraloncolytics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Oraloncolytics
Oraloncolytics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flatiron Health, Charm Health, Electronic Registry Systems, Jana Analysis and Asthenis, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flatiron.com | 2012 | New York, United States | $314.4M | 1,067 | Cloud-based oncology management tools are provided for cancer care providers. | |
| charmhealth.com.au | 2000 | Brisbane, Australia | – | – | SaaS oncology information systems are supplied for practitioner use. | |
| mycrstar.com | 2017 | Cincinnati, United States | – | 19 | Cloud-based technology is offered for oncology practice management and EHR. | |
| janaanalysis.com | 2016 | Chennai, India | – | 7 | Provides software solutions for electronic medical record management for oncologists. | |
| asthenis.de | 1998 | Aschheim, Germany | – | – | Developer of oncological documentation systems | |
| membercare.net | 2016 | Allen, United States | – | – | AI platform for scalable management of patient populations and personalized health experiences. | |
| oncims.co.ug | 2020 | Mbarara, Uganda | – | – | Delivers comprehensive information management platforms for cancer treatment and monitoring. |
Detailed competitors of Oraloncolytics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Oraloncolytics
10 companies that operate in the same segment as Oraloncolytics (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Oraloncolytics
Oraloncolytics was founded in 2018.
Oraloncolytics is headquartered in United States.
Shanthu Kere is the current CEO of Oraloncolytics. They have also founded this company.
Oraloncolytics provides practice management software tailored for oncology clinics through providing healthcare solutions, medical software, practice management, and oncology solutions. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Oraloncolytics's top competitors include Flatiron Health, Electronic Registry Systems and Asthenis.